Real-World Comparison of First-Line Atezolizumab plus Bevacizumab and Durvalumab plus Tremelimumab for Unresectable Hepatocellular Carcinoma

Atsushi Hiraoka, Toshifumi Tada, Masashi Hirooka, Kazuya Kariyama, Joji Tani, Masanori Atsukawa, Koichi Takaguchi, Ei Itobayashi, Takashi Nishimura, Kunihiko Tsuji, Toru Ishikawa, Kazuto Tajiri, Hironori Tanaka, Hidenori Toyoda, Chikara Ogawa, Takeshi Hatanaka, Satoru Kakizaki, Kazuhito Kawata, Atsushi Naganuma, Hisashi Kosaka, Tomomitsu Matono, Hidekatsu Kuroda, Yutaka Yata, Hiroki Nishikawa, Michitaka Imai, Tomoko Aoki, Hironori Ochi, Hideyuki Tamai, Shohei Komatsu, Takanori Matsuura, Yoshihide Ueda, Soo Ki Kim, Hideko Ohama, Fujimasa Tada, Shinichiro Nakamura, Yoshiko Nakamura, Osamu Yoshida, Kazuhiro Nouso, Asahiro Morishita, Norio Itokawa, Tomomi Okubo, Taeang Arai, Akemi Tsutsui, Takuya Nagano, Shinya Fukunishi, Kazunari Tanaka, Yuichi Koshiyama, Yuki Kanayama, Hidenao Noritake, Hirayuki Enomoto, Kosuke Matsui, Masaki Kaibori, Jumpei Okamura, Takumi Fukumoto, Yoichi Hiasa, Masatoshi Kudo, Takashi Kumada, Unknown, Unknown

Open source

DOI: 10.1159/000550924
Published: 2026-04-02
Container: Liver Cancer
Publisher: S. Karger AG
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1159/000550924,
  title = {Real-World Comparison of First-Line Atezolizumab plus Bevacizumab and Durvalumab plus Tremelimumab for Unresectable Hepatocellular Carcinoma},
  author = {Atsushi Hiraoka and Toshifumi Tada and Masashi Hirooka and Kazuya Kariyama and Joji Tani and Masanori Atsukawa and Koichi Takaguchi and Ei Itobayashi and Takashi Nishimura and Kunihiko Tsuji and Toru Ishikawa and Kazuto Tajiri and Hironori Tanaka and Hidenori Toyoda and Chikara Ogawa and Takeshi Hatanaka and Satoru Kakizaki and Kazuhito Kawata and Atsushi Naganuma and Hisashi Kosaka and Tomomitsu Matono and Hidekatsu Kuroda and Yutaka Yata and Hiroki Nishikawa and Michitaka Imai and Tomoko Aoki and Hironori Ochi and Hideyuki Tamai and Shohei Komatsu and Takanori Matsuura and Yoshihide Ueda and Soo Ki Kim and Hideko Ohama and Fujimasa Tada and Shinichiro Nakamura and Yoshiko Nakamura and Osamu Yoshida and Kazuhiro Nouso and Asahiro Morishita and Norio Itokawa and Tomomi Okubo and Taeang Arai and Akemi Tsutsui and Takuya Nagano and Shinya Fukunishi and Kazunari Tanaka and Yuichi Koshiyama and Yuki Kanayama and Hidenao Noritake and Hirayuki Enomoto and Kosuke Matsui and Masaki Kaibori and Jumpei Okamura and Takumi Fukumoto and Yoichi Hiasa and Masatoshi Kudo and Takashi Kumada and Unknown and Unknown},
  year = {2026},
  journal = {Liver Cancer},
  doi = {10.1159/000550924},
  url = {https://doi.org/10.1159/000550924}
}

RIS

TY  - JOUR
TI  - Real-World Comparison of First-Line Atezolizumab plus Bevacizumab and Durvalumab plus Tremelimumab for Unresectable Hepatocellular Carcinoma
AU  - Atsushi Hiraoka
AU  - Toshifumi Tada
AU  - Masashi Hirooka
AU  - Kazuya Kariyama
AU  - Joji Tani
AU  - Masanori Atsukawa
AU  - Koichi Takaguchi
AU  - Ei Itobayashi
AU  - Takashi Nishimura
AU  - Kunihiko Tsuji
AU  - Toru Ishikawa
AU  - Kazuto Tajiri
AU  - Hironori Tanaka
AU  - Hidenori Toyoda
AU  - Chikara Ogawa
AU  - Takeshi Hatanaka
AU  - Satoru Kakizaki
AU  - Kazuhito Kawata
AU  - Atsushi Naganuma
AU  - Hisashi Kosaka
AU  - Tomomitsu Matono
AU  - Hidekatsu Kuroda
AU  - Yutaka Yata
AU  - Hiroki Nishikawa
AU  - Michitaka Imai
AU  - Tomoko Aoki
AU  - Hironori Ochi
AU  - Hideyuki Tamai
AU  - Shohei Komatsu
AU  - Takanori Matsuura
AU  - Yoshihide Ueda
AU  - Soo Ki Kim
AU  - Hideko Ohama
AU  - Fujimasa Tada
AU  - Shinichiro Nakamura
AU  - Yoshiko Nakamura
AU  - Osamu Yoshida
AU  - Kazuhiro Nouso
AU  - Asahiro Morishita
AU  - Norio Itokawa
AU  - Tomomi Okubo
AU  - Taeang Arai
AU  - Akemi Tsutsui
AU  - Takuya Nagano
AU  - Shinya Fukunishi
AU  - Kazunari Tanaka
AU  - Yuichi Koshiyama
AU  - Yuki Kanayama
AU  - Hidenao Noritake
AU  - Hirayuki Enomoto
AU  - Kosuke Matsui
AU  - Masaki Kaibori
AU  - Jumpei Okamura
AU  - Takumi Fukumoto
AU  - Yoichi Hiasa
AU  - Masatoshi Kudo
AU  - Takashi Kumada
AU  - Unknown
AU  - Unknown
PY  - 2026
JO  - Liver Cancer
DO  - 10.1159/000550924
UR  - https://doi.org/10.1159/000550924
ER  -

APA

Hiraoka, A., Tada, T., Hirooka, M., Kariyama, K., Tani, J., Atsukawa, M., Takaguchi, K., Itobayashi, E., Nishimura, T., Tsuji, K., Ishikawa, T., Tajiri, K., Tanaka, H., Toyoda, H., Ogawa, C., Hatanaka, T., Kakizaki, S., Kawata, K., Naganuma, A., Kosaka, H., Matono, T., Kuroda, H., Yata, Y., Nishikawa, H., Imai, M., Aoki, T., Ochi, H., Tamai, H., Komatsu, S., Matsuura, T., Ueda, Y., Kim, S. K., Ohama, H., Tada, F., Nakamura, S., Nakamura, Y., Yoshida, O., Nouso, K., Morishita, A., Itokawa, N., Okubo, T., Arai, T., Tsutsui, A., Nagano, T., Fukunishi, S., Tanaka, K., Koshiyama, Y., Kanayama, Y., Noritake, H., Enomoto, H., Matsui, K., Kaibori, M., Okamura, J., Fukumoto, T., Hiasa, Y., Kudo, M., Kumada, T., Unknown, & Unknown (2026). Real-World Comparison of First-Line Atezolizumab plus Bevacizumab and Durvalumab plus Tremelimumab for Unresectable Hepatocellular Carcinoma. Liver Cancer. https://doi.org/10.1159/000550924

Source records

crossref · retrieved 2026-09-26T20:29:42.244Z